Introduction
B cells are considered pathogenic effectors in the context of autoimmune and inflammatory diseases because of their production of autoantibodies and inflammatory cytokines. Their activity, however, seems bilateral (1, 2) ; recent studies have revealed that B-lineage cells have the potential to produce anti-inflammatory cytokines. IL-10-competent B cells, for example, are referred to as 'regulatory B cells' based on their suppressive function in a variety of pathogenic disorders such as experimental autoimmune encephalomyelitis (EAE, a mouse model of multiple sclerosis (3)), collagen-induced arthritis (CIA) (4), inflammatory bowel disease (5), contact hypersensitivity (CHS) (6) , asthma (7) and adipose inflammation (8) . The practical animal models and recently developed marker systems facilitate the identification of important landmarks in B-cell regulatory function. Nevertheless, the establishment of a set of key signaling events to define the identity and physiological significance of such inhibitory B cells remains a challenge. This review focuses on the increasing evidence for signals that control the development and function of IL-10-producing B cells/plasmablasts and highlights the underlying molecular mechanisms of this control; it is based primarily on our own data.
Signals for regulatory B-cell function
Although a precise, common phenotypic signature of IL-10-competent (IL-10-producing) B-cell subsets is not known, the surface features of such cells have been revealed in recent studies. CD1d hi B cells in mesenteric lymph node (LN) have been shown to inhibit chronic intestinal inflammation in an IL-10-dependent manner (5) , and splenic marginal zone precursor (MZP) B cells with the transitional 2 (T2) phenotype CD21 hi CD23 + IgM hi (T2-MZP) are known to produce IL-10 in response to CD40 and B-cell receptor (BCR) stimulation and to inhibit CIA (9) . IL-10-competent CD1d hi CD5 + B cells (B10) in the spleen have been identified as regulatory B cells that ameliorate CHS (6) , EAE (10) and CIA (11) . TIM domain protein 1 (TIM1)-expressing B cells have also been shown to be IL-10-competent (12) . These cell subsets exhibit some overlap in terms of phenotype and are identified by mitogen-stimulated IL-10 expression in vitro. IL-10 reporter mice were recently used to identify CD138 hi plasma cells in spleen (13, 14) are considered contributors to the inhibitory roles of B cells (Table 2) . A consensus is developing that TLRs (16), CD40 (3, 4) , BCR (3) and combinations of them drive the signaling that confers a suppressive role on B cells.
TLR, CD40 and BCR signaling for IL-10 production by B cells
Many studies have established TLR signaling to be essential for IL-10 production (2, 29) . In vitro stimulation with TLRs induces IL-10 production by naive B cells; however, upon stimulation with BCR and CD40, naive B cells do not secrete 29) . Although the indispensability of TLR signals for CD40-CD40L interaction induces B-cell activation and plasma cell differentiation. CD40 ligation on B cells results in activation of STAT3, NF-κB and extracellular-signalregulated kinases (ERK), which are suggested regulators of IL-10 production in T cells, dendritic cells and macrophages (30) . Although there is no direct evidence in murine B cells, CD40 engagement induced marked activation of STAT3 and enhanced IL-10 secretion by human naive B cells (27, 31) .
Evidence for the mechanism by which the BCR signaling pathway contributes to B-cell IL-10 production is increasing. Upon encountering their cognate antigens via BCR, B cells are activated and differentiate into plasma cells. A key response to BCR stimulation is the increase in cytosolic Ca 2+ concentration due to the release of Ca 2+ from the endoplasmic reticulum (ER) and Ca 2+ influx from the extracellular space (32) . BCR stimulation activates the proximal kinases, subsequently activating phospholipase C-γ2 (PLCγ2) induces the STIM proteins to cluster below the plasma membrane, where they physically interact with Ca 2+ channels, leading to SOCE. For a long time, the physiological significance of SOCE was unknown, until a STIM-dependent SOCE was identified as a key signal for B-cell regulatory function through IL-10 production (25). Mice with B-cell-specific deletions of STIM proteins exhibited marked exacerbation of EAE development, and B cells lacking both STIM proteins failed to secrete BCRmediated IL-10. The importance of BCR signals for B-cell IL-10 production is further suggested by a study showing that mice lacking BLNK have impaired IL-10 production and increased CHS inflammation (26) .
How does Ca 2+ signaling control IL-10 production? A wide variety of Ca 2+ -dependent signaling molecules and transcription factors including CREB (cyclic adenosine monophosphate response element-binding protein), NF-κB, ERK, Jnk, p38 and NFAT family have been described as candidate regulators of IL-10 expression (30); however, in the case of B cells, the activation status of only NFAT1 (NFATc2) was impaired in the absence of STIM proteins (25) . NFAT1 is dephosphorylated by Ca 2+ -activated phosphatase calcineurin and translocates into the nucleus, where it becomes transcriptionally active. The calcineurin inhibitor cyclosporine A (CsA) was found to completely suppress IL-10 secretion, and silencing of NFAT1 greatly lowered IL-10 production. These findings are consistent with other findings that show the calcineurin-NFAT pathway to be involved in IL-10 production in other immune cells (35, 36) . Collectively, data suggest that the BCR-STIM-SOCEcalcineurin/NFAT signaling cascade may be essential for IL-10 production by B cells (Fig. 1) . It should be noted, however, that B-cell-specific ablation of NFAT2 (NFATc1), an inducible NFAT, was found to result in an increase in IL-10-competent B cells Fig. 1 . A model of signaling pathway for B-cell IL-10 production through TLRs, CD40 and BCR. TLRs and CD40 regulate IRF4, STAT3 and Blimp1, which induce the differentiation of B cells into regulatory plasmablasts and/or plasma cells. IRF4 may control direct IL-10 expression cooperated with BCR-mediated NFAT. BCR engagement activates proximal tyrosine kinases and PLCγ2 through BLNK, leading to generate IP 3 . IP 3 binds the IP 3 R in the membrane of the ER, resulting in Ca 2+ release. The decrease of Ca 2+ concentration in luminal ER causes the translocation of STIM1 underneath the plasma membrane, which in turn opens Ca 2+ channel (SOCE, store-operated Ca 2+ entry). SOCE activates calcineurin, which results in NFAT activation through its dephosphorylation and translocation into the nucleus.
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(37), suggesting that members of the NFAT family may have distinct roles in IL-10 expression.
Although B cells can secrete IL-10 after BCR stimulation in a Ca 2+ influx-dependent way, this occurs only when B cells are pre-stimulated with CD40 and, particularly, TLR agonists such as LPS (15, 25) . Why is BCR stimulation alone not sufficient for B-cell IL-10 production? Given that NFAT activation is normally observed after stimulation by BCR alone, additional signals might be required. One possible explanation is that TLR signals may alter the chromatin structure at the il10 locus, thereby allowing key transcription factors to access the promoter/ enhancer of il10. Indeed, previous studies have suggested the participation of chromatin remodeling in the initial events leading to IL-10 transcription in several immune cells (30) . Histone deacetylase 11 (HDAC11) has been shown to associate with the distal region of the il10 gene locus and to repress LPSmediated IL-10 production in antigen-presenting cells (38) . Since histone deacetylation mediated by HDAC leads to a silent chromatin, HDAC11 may regulate chromatin status and the transcription factor required for IL-10 mRNA transcription.
The most likely scenario is that CD40 and TLR ligation allows B cells to differentiate into IL-10-competent/producing B cells in which NFAT1, for example, augments IL-10 expression. Given that such stimulators are well-known inducers of plasma cell differentiation, it is reasonable to expect that differentiated plasmablasts or plasma cells are IL-10 producers, as discussed below. In association with this idea, TLR downstream molecules may also function as transcriptional partners of NFAT for IL-10 expression. Indeed, NFAT proteins interact with several transcription factors, including AP-1, IRF4, GATA-binding protein 3 (GATA3) and c-Maf to produce various cytokines in T cells (39) , which suggests that additional TLRactivated components may be required for IL-10 production in B cells or for regulatory B-lineage cell development.
Signals controlling the development of IL-10-producing B cells and plasmablasts
Much has been learned about the signals governing regulatory B-cell function, while their contribution to the ontology of IL-10-producing B cells is a challenging issue. As described above, it seems likely that the TLR and CD40 signals may enable B-cell IL-10 expression via differentiation into IL-10-competent plasmablasts or plasma cells (Fig. 1) . A recent study (15) has provided evidence to support this hypothesis; it is well known that upon stimulation with LPS, naive B cells give rise to CD138 + plasmablasts/plasma cells. When IL-10 secretion was assessed in these CD138 + plasmablasts/plasma cells and CD138 − B cells upon BCR stimulation, CD138 + cells were found to predominantly produce IL-10. The observed IL-10 secretion was completely Ca 2+ influxdependent because CD138 + cells lacking STIM1/2 failed to produce IL-10 (Y. Baba et al., unpublished data). In agreement with this, developing plasmablasts expressing Blimp1, the master transcription factor for plasma cell differentiation, exhibited marked IL-10 production, while Blimp1 − cells did not (15) . This observation has been extended to physiological and pathological conditions; in EAE in IL-10 reporter mice that carry a Venus transgene following the endogenous il10 locus, IL-10/Venus-positive cells were not detectable in B10 and T2-MZP cells in spleen, but were predominantly found in the CD138 + CD44
hi population in the draining LN. Notably, this IL-10
hi subset of cells was newly generated after EAE induction independent of the germinal center response. Since these cells were highly proliferative and expressed low levels of Blimp1, they were considered to be IL-10-producing plasmablasts. Although splenic CD138 + cells also express Venus, albeit less efficiently than draining LN plasmablasts, they are non-divided and highly Blimp1-expressing plasma cells, the absolute number of which is not increased during EAE. Importantly, mice with B-cell-specific deletions of genes essential for plasma cell generation (irf4 and prdm1) develop more severe EAE than control mice, indicating that endogenous plasmablasts serve as regulatory B cells. This leads to the hypothesis that regulatory plasmablasts are generated only in an inflammatory environment as a result of a negative feedback mechanism (Fig. 2) . Shen et al. demonstrated that CD138 hi plasma cells that express IL-10 as well as IL-35 accumulate in the spleen during Salmonella typhimurium infection in the B-Green IL-10 reporter mouse strain (14) ; however, the authors did not indicate whether splenic plasma cells express IL-10 in these reporter mice during EAE. It has been shown in an MRL.Fas lpr mouse model of systemic lupus erythematosus (SLE) that CD138 + plasmablasts in spleen and more frequently in draining LN are major subsets of IL-10-producing B-lineage cells, as shown using 10BiT IL-10 reporter mice (40) .
In contrast, well-studied regulatory B-cell subsets have been identified as Pax5 + B cells, plasmablasts and plasma cells) is a separate, independent subset or there is a developmental connection among these populations (Fig. 2) .
Most studies on regulatory B cells have been focused on splenic B cells and plasma cells; however, one study has addressed the important question of where regulatory B cells exist and exert their suppressive function (15) ; the depletion of splenic B cells by splenectomy did not affect EAE pathogenesis, suggesting a poor contribution of splenic B cells to EAE amelioration. Instead, in mice lacking B cells in all peripheral LN following B-cell-specific ablation of CD62L, exacerbated EAE and impaired plasmablast generation in the draining LN were observed (15) . This suggests that in EAE, B cells perform their suppressive role in the draining LN. On the other hand, previous studies have indicated a functionally important role of splenic B cells to reduce EAE in adaptive transfer experiments (10, 11) . One explanation for this observation is that these splenic B cells would give rise to plasmablasts in the draining LN after transfer. Indeed, transferred whole splenic B cells were detected in the draining LN in EAE mice, and their plasmablast generation was required for disease remission. Additionally, adoptive transfer of B10 cells from mice lacking IL-21R, CD40, polyclonal BCR and MHCII, which are indispensable for plasma cell differentiation (41, 42) , does not inhibit EAE development (17, 18) . Splenic regulatory B cells may therefore serve as plasmablast precursors in an adoptive transfer setting. In the case of systemic infection, splenic CD138 hi plasma cells expressed IL-10 (13, 14) . A unique CD19 + B-cell subset in adipose tissue constitutively expressing IL-10 was recently demonstrated to suppress adipose inflammation (8) . Therefore, whether cells produced at different sites and diseases are phenotypically and functionally specialized and stable because of distinct types of inflammation (e.g. systemic or local) remains to be investigated as a possible explanation for the observed complexities.
It is important to note how regulatory B-cell development is molecularly controlled. IRF4, a critical factor in the early phase of plasma cell differentiation and one of the downstream targets of TLR, CD40 and BCR signaling, seems essential for regulatory B-cell development and IL-10 expression. The absence of IRF4 in B cells results in impaired BCR-mediated IL-10 expression and plasmablast generation in vitro (15) . The in vivo importance of IRF4 has been demonstrated by the severe EAE pathogenesis in mice with B cells lacking IRF4. IRF4 in plasmablasts is furthermore bound to the il10 CNS9 region (Fig. 1) , which controls il10 expression and is located ~9.1 kb upstream of the transcription start site (43, 44) . Considering a previous report of NFAT binding to the il10 CNS9 region in T cells (45) , IRF4 may serve as an NFAT transcription partner to produce IL-10 in plasmablasts. IRF4 may thus control both il10 transcription and generation of IL-10-competent plasmablasts. Blimp1 is another candidate molecule that controls IL-10 production since Blimp1 + plasmablasts exclusively produce IL-10, which contribute to EAE suppression. Blimp1-deficient B cells, however, produce IL-10 normally in vitro despite impaired CD138 + cell generation. Considering that B cells lacking Blimp1 fail to fully differentiate into plasma cells but can initiate this differentiation pathway (46) (47) (48) , it seems possible that Blimp1 in developing plasmablasts may not directly regulate IL-10 expression.
IL-10 production by human B cells
The identification of murine regulatory B cells raises the question about their human counterparts. There is now evidence for the existence of a subset of human plasmablasts representing IL-10-producing B cells as is the case in mice (15) . B cells isolated from the peripheral blood of healthy individuals and cultured with CpG (a TLR9 agonist) generate CD27 hi CD38
+ putative plasmablasts. In the presence of CpG and cytokine cocktails including IL-2, IL-6 and IFNs, which are known to provide conditions for effective plasmablast differentiation (49, 50) 
CD38
hi immature B cells have been reported to include regulatory B cells that produce IL-10 after co-culture with CD40L-expressing CHO cells, thereby inhibiting T-cell cytokine production (27) . This cell population demonstrates reduced function in SLE patients compared with healthy controls. In another study, CD24 hi CD27 + B cells were found to produce IL-10 upon CD40 and TLR stimulation and to negatively regulate monocyte tumor necrosis factor-α production (51) . Different human regulatory B-cell subsets may thus exist and play roles at different layers, or the in vitro stimulation (CD40, TLRs) to evoke IL-10 secretion may all induce the initiation of the plasmablast differentiation program. 
− memory-like B cells do so only poorly (15) . Taking into account the fact that in the context of autoimmunity, switched memory B cells represent the source of pathogenic autoantibodies, the immediate precursor of
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developing plasmablasts would dictate the balance between cells that promote autoimmunity by antibody secretion or have a regulatory ability that protects from pathology. The characteristics of IgM-or IgG-secreting plasmablasts with regulatory or pathogenic function and the parental relationship between such plasmablasts and the B-cell subset (immature, mature, memory) warrant further investigation.
Although the signaling cascade for human IL-10 production by B cells is not as well studied as the corresponding murine system, signaling pathways common to those in murine cells may apply in humans too, given that similar stimulants (e.g. TLRs, CD40, and BCR) are present in both systems. Signal transduction mediated by IFNs is emerging as another valuable inducer of regulatory B cells; IFNs are essential cytokines for host innate immune responses against viral infections (52, 53) , and they enable B cells to modulate humoral immunity through immunoglobulin class-switch recombination and plasma cell differentiation in mice and humans (49, (54) (55) (56) . It has been suggested that IFNs do not drive IL-10 expression directly, but that they can amplify TLR-mediated IL-10 production in part due to increased expression of MyD88, a TLR signaling adaptor molecule ( Fig. 1) (24) . Given that IFNs are involved in the pathogenesis of human autoimmune diseases, such inflammatory conditions may induce not only autoantibody-secreting plasma cells, but also IL-10-producing regulatory plasmablasts to inhibit excess inflammation.
Conclusions
A growing appreciation of the extent of regulatory functions of B-cell subsets and the mechanisms operating in such cells raises several important questions of whether there is a master gene for regulatory B-cell generation, whether the subsets of regulatory B cells differ by virtue of disease models or species, whether IL-10-producing plasmablasts secrete other cytokines and differentiate into long-lived plasma cells, whether an unidentified mechanism exists for the suppressive function of B cells except IL-10 and whether regulatory T cells, essentially important for limiting inflammation, and regulatory B cells play their role coordinately or independently. Especially in the context of human disease, it is imperative to determine the extent to which regulatory B cells/plasmablasts contribute to the negative regulation of the pathology in autoimmune diseases, inflammation, obesity and cancer. While the consensus regarding these matters hinges on coherent definition and significant research progress, this smorgasbord of interesting questions represents a notable challenge in terms of understanding the whole picture of the inhibitory role of B-cells and its clinical relevance. 
